Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.

Keyphrases